Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection

Bone Marrow Transplantation volume 57, pages 176–182 (2022)Cite this article

Subjects

Abstract

Traceability of patients who are candidates for Hematopoietic cell transplant (HCT) is crucial to ensure HCT program quality. Continuous knowledge of both a detailed registry from a HCT program and final exclusion causes can contribute to promoting a real-life vision and optimizing patient and donor selection. We analyzed epidemiological data reported in a 4 year-monocentric prospective registry, which included all patients presented as candidates for autologous (Auto) and/or allogeneic (Allo) HCT. A total of 543 patients were considered for HCT: 252 (42.4%) for Allo and 291 (57.6%) for Auto. A total of 98 (38.9%) patients were excluded from AlloHCT due to basal disease progression more commonly (18.2%). Seventy-six (30.2%) patients had an HLA identical sibling, whereas 147 (58.3%) patients had only Haplo. UD research was performed in 106 (42%) cases, significantly more often in myeloid than lymphoid malignancies (57% vs 28.7%, p < 0.001) but 61.3% were finally canceled, due to donor or disease causes in 72.4%. With respect to Auto candidates, a total of 60 (20.6%) patients were finally excluded; progression was the most common cause (12%). Currently, Haplo is the most frequent donor type. The high cancellation rate of UD research should be revised to optimize further donor algorithms.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Flow chart of patients by basal disease.

Similar content being viewed by others

References

  1. Snowden JA, McGrath E, Duarte RF, Saccardi R, Orchard K, Worel N, et al. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. Bone Marrow Transplant. 2017;52:1367–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Gratwohl A, Brand R, McGrath E, van Biezen A, Sureda A, Ljungman P, et al. Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation. Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation, and the European Leukemia Net. Haematologica. 2014;99:908–15.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transpl. 2019;54:1525–52.

    Article  Google Scholar 

  4. Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, et al. Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1739–48.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transpl. 2017;52:811–7.

    Article  CAS  Google Scholar 

  6. Lown RN, Marsh SGE, Switzer GE, Latham KA, Madrigal JA, Shaw BE. Ethnicity, length of time on the register and sex predict donor availability at the confirmatory typing stage. Bone Marrow Transpl. 2014;49:525–31.

    Article  CAS  Google Scholar 

  7. Karam E, Laporte J, Solomon SR, Morris LE, Zhang X, Holland HK, et al. Who is a better donor for recipients of allogeneic hematopoietic cell transplantation: a young HLA-mismatched haploidentical relative or an older fully HLA-matched sibling or unrelated donor? Biol Blood Marrow Transpl. 2019;25:2054–60.

    Article  Google Scholar 

  8. Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127:260–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. McCurdy SR, Fuchs EJ. Selecting the best haploidentical donor. Semin Hematol. 2016;53:246–51.

    Article  PubMed  Google Scholar 

  10. Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, et al. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transpl. 2020;55:681–94.

    Article  CAS  Google Scholar 

  11. Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2016;51:1283–1300.

    Article  CAS  Google Scholar 

  12. Cao K, Chopek M, Fernández-Viña MA. High and intermediate resolution DNA typing systems for class I HLA-A, B, C genes by hybridization with sequence-specific oligonucleotide probes (SSOP). Rev Immunogenet. 1999;1:177–208.

    CAS  PubMed  Google Scholar 

  13. Erlich H. HLA DNA typing: past, present, and future. Tissue Antigens. 2012;80:1–11.

    Article  CAS  PubMed  Google Scholar 

  14. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010;303:1617–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, et al. Worldwide network for blood and marrow transplantation recommendations for establishing a hematopoietic cell transplantation program, Part I: minimum requirements and beyond. Biol Blood Marrow Transpl. 2019;25:2322–9.

    Article  Google Scholar 

  16. Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43:676–81.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Dahi PB, Lazarus HM, Sauter CS, Giralt SA. Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma. Bone Marrow Transpl. 2019;54:943–60.

    Article  Google Scholar 

  18. Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS. Acute myeloid leukemia: the good, the bad, and the ugly. Am Soc Clin Oncol Educ Book. 2018;38:555–73.

    Article  PubMed  Google Scholar 

  19. von Tresckow B, Engert A. The role of autologous transplantation in Hodgkin lymphoma. Curr Hematol Malig Rep. 2011;6:172–9.

    Article  Google Scholar 

  20. Lahoud OB, Sauter CS, Hamlin PA, Dahi PB. High-dose chemotherapy and autologous stem cell transplant in older patients with lymphoma. Curr Oncol Rep. 2015;17:42.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hu B, Jacobs R, Ghosh N. Checkpoint inhibitors hodgkin lymphoma and non-hodgkin lymphoma. Curr Hematol Malig Rep. 2018;13:543–54.

    Article  PubMed  Google Scholar 

  22. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy. Biol Blood Marrow Transpl. 2019;25:2305–21.

    Article  CAS  Google Scholar 

  23. Tun AM, Ansell SM. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. Cancer Treat Rev. 2020;88:102042.

    Article  CAS  PubMed  Google Scholar 

  24. Klyuchnikov E, Bacher U, Kroll T, Shea TC, Lazarus HM, Bredeson C, et al. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Bone Marrow Transplant. 2014;49:1–7.

    Article  CAS  PubMed  Google Scholar 

  25. Richard-Carpentier G, DiNardo CD. Single-agent and combination biologics in acute myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2019;1:548–56.

    Article  Google Scholar 

  26. Choi JH, Bogenberger JM, Tibes R. Targeting apoptosis in acute myeloid leukemia: current status and future directions of BCL-2 inhibition with venetoclax and beyond. Target Oncol. 2020;15:147–62.

    Article  PubMed  Google Scholar 

  27. Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson. Leukemia. 2014;28:289–92.

    Article  CAS  PubMed  Google Scholar 

  28. Percival ME, Tao L, Medeiros BC, Clarke CA. Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: a SEER database analysis. Cancer. 2015;121:2004–12.

    Article  PubMed  Google Scholar 

  29. Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. Onco Targets Ther. 2016;9:4937–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Chen AT, Prchal JT. JAK2 kinase inhibitors and myeloproliferative disorders. Curr Opin Hematol. 2010;17:110–6.

    Article  CAS  PubMed  Google Scholar 

  31. Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol. 2016;91:50–58.

    Article  CAS  PubMed  Google Scholar 

  32. Balassa K, Griffiths A, Winstone D, Li Y, Rocha V, Pawson R. Attrition at the final donor stage among unrelated haematopoietic stem cell donors: the British Bone Marrow Registry experience. Transfus Med. 2019;29:332–7.

    Article  CAS  PubMed  Google Scholar 

  33. Pidala J, Mupfudze TG, Payton T, Barker J, Perales MA, Shaw BE, et al. Urgent time to allogeneic hematopoietic cell transplantation: a national survey of transplant physicians and unrelated donor search coordinators facilitated by the histocompatibility advisory group to the national marrow donor program. Biol Blood Marrow Transpl. 2019;25:2501–6.

    Article  Google Scholar 

  34. Dehn J, Setterholm M, Buck K, Kempenich J, Beduhn B, Gragert L, et al. HapLogic: a predictive human leukocyte antigen-matching algorithm to enhance rapid identification of the optimal unrelated hematopoietic stem cell sources for transplantation. Biol Blood Marrow Transpl. 2016;22:2038–46.

    Article  CAS  Google Scholar 

  35. Fuchs E, O’Donnell PV, Brunstein CG. Alternative transplant donor sources: is there any consensus? Curr Opin Oncol. 2013;25:173–9.

    Article  CAS  PubMed  Google Scholar 

  36. Kindwall-Keller TL, Ballen KK. Alternative donor graft sources for adults with hematologic malignancies: a donor for all patients in 2017! Oncologist. 2017;22:1125–34.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Passweg JR, Baldomero H, Bader P, Basak GW, Bonini C, Duarte R, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transpl. 2018;53:1139–48.

    Article  CAS  Google Scholar 

  38. D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transpl. 2020;26:e177–e182.

    Article  Google Scholar 

  39. Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573–e584.

    Article  PubMed  Google Scholar 

  40. Ruggeri A, Labopin M, Savani B, Paviglianiti A, Blaise D, Volt F, et al. Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. Bone Marrow Transpl. 2019;54:1987–94.

    Article  CAS  Google Scholar 

  41. Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang XJ, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transpl. 2020;55:12–24.

    Article  CAS  Google Scholar 

  42. Tiercy JM. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica. 2016;101:680–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Baker M, Wang H, Rowley SD, Cai L, Pecora AL, Skarbnik A, et al. Comparative outcomes after haploidentical or unrelated donor bone marrow or blood stem cell transplantation in adult patients with hematological malignancies. Biol Blood Marrow Transpl. 2016;22:2047–55.

    Article  Google Scholar 

  44. Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M, Solh M, et al. Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transpl. 2016;22:125–33.

    Article  CAS  Google Scholar 

  45. Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13:46.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Martínez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for hodgkin lymphoma: a registry study of the lymphoma working party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017;35:3425–32.

    Article  PubMed  Google Scholar 

  47. Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, et al. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019;3:360–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank CERCA Programme/Generalitat de Catalunya for institutional support. We thank the entire medical and nurse staff of ICO centers and referral regional centers who participate in our weekly HCT committee.

Author information

Authors and Affiliations

  1. Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, Barcelona, Spain

    R. Parody, I. Sánchez-Ortega, A. Mussetti, B. Patiño, M. Arnan, H. Pomares, E. González-Barca, S. Mercadal, C. Boqué, C. Maluquer, I. Carro, M. Peña, V. Clapés, S. Verdesoto, G. Bustamante, AC. Oliveira, C. Baca, Mar Sánchez-Salmerón, E. Domingo-Domènech & A. Sureda

  2. Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain

    R. Parody, A. Mussetti, E. González-Barca, S. Mercadal, C. Boqué, C. Maluquer, I. Carro, M. Peña, E. Domingo-Domènech & A. Sureda

  3. EBMT medical Office; 3. Hospital Moisès Broggi, S.Joan d’Espí, Barcelona, Spain

    I. Sánchez-Ortega, S. Verdesoto, G. Bustamante & E. Cabezudo

  4. H. Comarcal d’Alt Penedés, Vilafranca del Penedés, Barcelona, Spain

    V. Clapés

  5. Hospital Sant Camil - St. Pere de Ribes, Barcelona, Spain

    AC. Oliveira

  6. H General de Igualada, Barcelona, Spain

    C. Baca

  7. Institut Català d’Oncologia-Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain

    C. Talarn & L. Escoda

  8. Banc de Sang i Teixits, Barcelona, Barcelona, Spain

    S. Ortega, N. García & M. Isabel González-Medina

  9. REDMO, Fundació Josep Carreras, Barcelona, Spain

    C. Fusté, J. Villa & E. Carreras

Authors
  1. R. Parody
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Sánchez-Ortega
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Mussetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Patiño
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Arnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Pomares
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. González-Barca
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Mercadal
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Boqué
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. Maluquer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. I. Carro
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. Peña
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. V. Clapés
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. S. Verdesoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. G. Bustamante
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. AC. Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. C. Baca
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. E. Cabezudo
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. C. Talarn
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. L. Escoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. S. Ortega
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. N. García
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. M. Isabel González-Medina
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Mar Sánchez-Salmerón
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. C. Fusté
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. J. Villa
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. E. Carreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. E. Domingo-Domènech
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. A. Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RP was responsible of study design, overall analysis and writing of first draft; ISO, AM and AS helped in overall analysis, interpretation and writing; all the remaining authors reviewed the manuscript and approved the final draft.

Corresponding author

Correspondence to R. Parody.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Parody, R., Sánchez-Ortega, I., Mussetti, A. et al. A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection. Bone Marrow Transplant 57, 176–182 (2022). https://doi.org/10.1038/s41409-021-01506-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01506-4

Search

Advanced search

Quick links